title: Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007.
abstract: A consensus conference including thirty experts was held in April, 2007, to discuss risk factors for breast cancer and their management. Four categories of risk were outlined, from breast cancer "average" through "very high" risk, the latter including individuals with high penetrance BRCA1/2 gene mutations. Guidelines for management of patients in each of these categories were discussed, with the major portion of the conference being devoted to individuals with BRCA1/2 mutations. Prevalence of these mutations in the general populations was estimated to be 1 in 250-500 individuals, with an increased prevalence in Ashkenazic Jews and other founder groups. Risk reduction strategies for these individuals include surveillance, with or without chemoprevention drugs, or surgical procedures to remove the organs at risk, i.e., bilateral mastectomy and/or bilateral salpingo-oophorectomy. These risk reduction strategies were evaluated fully, and recommendations were made for the care of patients in each of the risk categories. These guidelines for patient care were approved by the entire group of experts.
authors.affiliation: Jefferson Medical College, 1015 Chestnut Street, Suite 510, Philadelphia, PA 19107-4305, USA. gordonschwartz@yahoo.com
authors.forename: Gordon F
authors.initials: GF
authors.lastname: Schwartz
authors.forename: Kevin S
authors.initials: KS
authors.lastname: Hughes
authors.forename: Henry T
authors.initials: HT
authors.lastname: Lynch
authors.forename: Carol J
authors.initials: CJ
authors.lastname: Fabian
authors.forename: Ian S
authors.initials: IS
authors.lastname: Fentiman
authors.forename: Mark E
authors.initials: ME
authors.lastname: Robson
authors.forename: Susan M
authors.initials: SM
authors.lastname: Domchek
authors.forename: Lynn C
authors.initials: LC
authors.lastname: Hartmann
authors.forename: Roland
authors.initials: R
authors.lastname: Holland
authors.forename: David J
authors.initials: DJ
authors.lastname: Winchester
authors.forename: Benjamin O
authors.initials: BO
authors.lastname: Anderson
authors.forename: Banu K
authors.initials: BK
authors.lastname: Arun
authors.forename: Harry
authors.initials: H
authors.lastname: Bartelink
authors.forename: Philip
authors.initials: P
authors.lastname: Bernard
authors.forename: Bernardo
authors.initials: B
authors.lastname: Bonanni
authors.forename: Blake
authors.initials: B
authors.lastname: Cady
authors.forename: Krishna B
authors.initials: KB
authors.lastname: Clough
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Feig
authors.forename: Sylvia H
authors.initials: SH
authors.lastname: Heywang-Köbrunner
authors.forename: Anthony
authors.initials: A
authors.lastname: Howell
authors.forename: Claudine
authors.initials: C
authors.lastname: Isaacs
authors.forename: Daniel B
authors.initials: DB
authors.lastname: Kopans
authors.forename: Robert E
authors.initials: RE
authors.lastname: Mansel
authors.forename: Shahla
authors.initials: S
authors.lastname: Masood
authors.forename: Juan P
authors.initials: JP
authors.lastname: Palazzo
authors.forename: Peter I
authors.initials: PI
authors.lastname: Pressman
authors.forename: Lawrence J
authors.initials: LJ
authors.lastname: Solin
authors.forename: Michael
authors.initials: M
authors.lastname: Untch
mesh_terms: D001943:Breast Neoplasms / Q000209:etiology* / Q000235:genetics*; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D016158:Genes, p53; D005817:Genetic Counseling; D006801:Humans; D009154:Mutation; D051059:PTEN Phosphohydrolase / Q000235:genetics; D012307:Risk Factors; D012308:Risk Management
chemical_list: D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human